跳到主要內容

臺灣博碩士論文加值系統

(3.235.120.150) 您好!臺灣時間:2021/07/31 15:29
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:廖俊吉
研究生(外文):Jynu-Ji Liao
論文名稱:鳳仙花抗幽門螺旋桿菌活性、活性成分定量方法及萃取最適化之研究
論文名稱(外文):Anti-Helicobacter pylori activity, quantification of active compounds with an HPLC method and optimization of active compounds extraction from Impatiens balsamina L..
指導教授:王苑春
指導教授(外文):Yuan-Chuen Wang
學位類別:碩士
校院名稱:國立中興大學
系所名稱:食品暨應用生物科技學系
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
畢業學年度:96
語文別:中文
論文頁數:92
中文關鍵詞:幽門螺旋桿菌鳳仙花
相關次數:
  • 被引用被引用:0
  • 點閱點閱:141
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
幽門螺旋桿菌與胃炎、胃潰瘍及胃癌等有密切的相關性,世界衛生組織於1994年將幽門螺旋桿菌例為第一級致癌因子。抗生素為治療幽門螺旋桿菌感染之主要藥物,但隨著幽門螺旋桿菌之抗藥性日亦嚴重,各方學者不斷研究開發適合之替代藥物。鳳仙花 (Impatiens balsamina L.) 為台灣民間常用之藥物植物,用以治療風濕偏廢、腰腿疼痛等症狀,相關文獻亦證實鳳仙花具有抗過敏、抗搔癢及抗微生物等生理活性。本研究探討鳳仙花抗幽門螺旋桿菌活性;並開發一個簡單、快速之高效能液相層析法,以定量鳳仙花抗幽門螺旋桿菌成分;此外,亦探討鳳仙花抗幽門螺旋桿菌成分萃取最適化條件。
  鳳仙花抗幽門螺旋桿菌之研究結果顯示出,鳳仙花95%乙醇萃取物具有相當好之抗幽門螺旋桿菌活性,對11株cagA+及多重抗藥性菌株之MICs及MBCs值均為20 ~ 80 μg/mL。
在HPLC分析方法開發部分,以Mightysil RP-18 column為靜相,2%醋酸水及甲醇為移動相進行等位沖提,並於 UV 248 nm 偵測。compound B 及 compound A 在 25 ~ 300 μg/mL 的濃度範圍時,有良好的線性關係 (r2 分別為0.99994及0.99996)。二者之回收率範圍分別為100.5 ~ 101.1%及100.5 ~ 101.3%。同日間及異日間精密度之相對標準偏差均小於1%。偵測極限分別為3.68 × 10-2 及2.48 × 10-2 μg/mL,定量極限分別為1.11 × 10-1 及7.51 × 10-2 μg/mL。鳳仙花含有相當高含量之compound A,但未偵測到 compound B。
鳳仙花活性成分萃取最適化之結果顯示出,以丙酮為萃取溶劑,於中等溫度萃取,可得最大量之活性成分。
目錄
表次.................................................IV
圖次..................................................V
中文摘要..............................................1
英文摘要. .............................................3
壹、前言..............................................5
貳、文獻整理..........................................7
一、幽門螺旋桿菌之之生理、致病因子及根除..............7
(一)幽門螺旋桿菌之發展史..............................7
(二)幽門螺旋桿菌之特性................................8
(三)幽門螺旋桿菌之致病因子............................8
(四)幽門螺旋桿菌之流行病學調查.......................16
(五)幽門螺旋桿菌感染與宿主免疫反應...................16
(六)cagA+幽門螺旋桿菌與胃癌之關聯性..................18
二、幽門螺旋桿菌之治療與根除.........................18
(一)常用之根除方式及藥物.............................18
(二)幽門螺旋桿菌抗生素之抗藥性.......................20
三、天然物質抑制幽門螺旋桿菌之相關研究...............22
(一)藥用植物.........................................22
(二)天然植物.........................................25
(三)食物.............................................25
(四)微生物代謝產物...................................26
四、鳳仙花藥材及相關生理活性.........................26
(一)鳳仙花之分部及形態...............................26
(二)鳳仙花之傳統藥理作用.............................26
(三)鳳仙花之主要化學成分組成.........................28
(四)鳳仙花之生理活性.................................29
五、Compound A及生理活性.............................30
(一)抗微生物作用.....................................31
(二)抗過敏作用.......................................31
(三)抗腫瘤作用.......................................31
六、HPLC分析compound A及compound B方法之文獻回獻.....32
(一)單獨分析compound B方法之文獻.....................32
(二)單獨分析compound A方法之文獻.....................34
(三)同時分析compound B及compound A方法之文獻.........37
參、研究目的.........................................39
肆、材料與方法.......................................40
一、材料 ............................................40
(一)生藥材...........................................40
(二)化學試劑.........................................40
(三)儀器設備.........................................40
二、實驗方法.........................................42
第一部分:鳳仙花95%乙醇萃取物抗cagA+及抗藥性幽門
螺旋桿菌活性之研究
(一)鳳仙花95%乙醇萃取物製備..........................42
(二)菌株來源及培養...................................42
(三)萃取溶劑對幽門螺旋桿菌之抑制活性.................44
(四)最低抑菌濃度測定(Minimum inhibitory concentration,
MIC).............................................45
(五)最低殺菌濃度測定(Minimum bactericidal concentration,
MBC).............................................45
第二部分:以高效能液相層析法定量鳳仙花之抗幽門螺旋桿菌成
分,compound B及compound A
(一)HPLC分析條件 ...................................46
(二)分析方法專一性(Specificity)驗證..................46
(三)分析方法線性(Linearity)驗證......................47
(四)分析方法準確度(Accuracy)驗證.....................47
(五)分析方法精密度(Precision)驗證....................48
(六)偵測極限(Limit of detection)與定量極限(Limit of
quantitation)....................................49
(七)鳳仙花各部位compound B及compound A含量測定.......49
第三部分:鳳仙花抗幽門螺旋桿菌成分compound A萃取
最適化之探討
(一)萃取溶劑之影響...................................50
(二)萃取溶劑pH值之影響...............................51
(三)萃取溫度之影響...................................51
(四)萃取方法之影響...................................52
(五)統計分析.........................................53
伍、結果與討論
第一部分:鳳仙花95%乙醇萃取物抗cagA+及抗藥性幽門
螺旋桿菌活性之研究
(一)鳳仙花95%乙醇粗萃物萃取率........................55
(二)萃取溶劑對幽門螺旋桿菌之抑菌範圍.................55
(三)最低抑菌濃度測定(Minimum inhibitory concentration,
MIC).............................................55
(四)最低殺菌濃度測定(Minimum bactericidal concentration,
MBC).............................................59
第二部分:以高效能液相層析法定量鳳仙花之抗幽門螺旋桿菌成
分,compound B及compound A
(一)分析方法專一性驗證...............................62
(二)分析方法線性驗證.................................62
(三)分析方法準確度驗證...............................62
(四)分析方法精密度驗證...............................66
(五)分析方法偵測極限驗證.............................66
(六)分析方法定量極限驗證.............................66
(七)鳳仙花各部位compound B及compound A含量...........68
第三部分:鳳仙花抗幽門螺旋桿菌成分(compound A)萃取
最適化之探討
(一)萃取溶劑之影響...................................70
(二)萃取溶劑pH值之影響...............................72
(三)萃取溫度之影響...................................74
(四)萃取方法之影響...................................76
陸、結論.............................................78
柒、參考文獻.........................................79
丘年永、張光雄。1998。原色台灣藥用植物圖鑑(一)。南天書局。臺北。 P.144

胡喜蘭、朱慧、劉存瑞、屠鵬飛。2003。鳳仙花的化學成分研究。中成藥。25:833-834。

危建安、謝琪。2001。鳳仙花研究進展。時珍國醫國藥。12:164-164。

顏偉慧、陳潔。2006。兒童中幽門螺桿菌對阿莫西林耐藥性和耐藥機制的研究進展。國際兒科學期刊。33:129-131。

Atherton JC, Cao P, Peek RM, Tummuru MKR, Blaser MJ, Cover TL . 1995
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori - association of specific vacA types with cytotoxin production and peptic-ulceration. J Bio Chem 270: 17771-17777

Atherton JC, Peek RM Jr, Tham KT, Cover TL, Blaser MJ. 1997. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112:92-99.

Babula P, Mikelova R, Adam V, Kizek R, Havel L, Sladky Z. 2006. Using of liquid chromatography coupled with diode array detector for determination of naphthoquinones in plants and for investigation of influence of pH of cultivation medium on content of plumbagin in Dionaea muscipula. J Chromatogr B 842:28-35.

Backert S, Ziska E, Brinkmann V, Zimny-Arndt U, Fauconnier A, Jungblut PR, Naumann M, Meyer TF. 2000. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2:155-164.
Baldari CT, Lanzavecchia A, Telford JL. 2005. Immune subversion by Helicobacter pylori. Trends Immunol 26:199-207.

Bakkali AT, Jaziri M, Foriers A, Heyden YV, Vanhaelen M, Homes J. 1997. Lawsone accumulation in normal and transformed cultures of henna, Lawsonia inermis. Plant Cell Tissue Organ Cult 51:83-87.

Blaser MJ. 1993. Helicobacter pylori: microbiology of a ''slow'' bacterial
infection. Trends Microbiol 1:255-260.

Blaser MJ, Atherton JC. 2004. Helicobacter pylori persistence: biology and disease. J Clin Invest 113: 321-333.

Bolanle AA and Festus MA. 2004. In vitro anti-Helicobacter pylori potential of methanol extract of Allium ascalonicum Linn. (Liliaceae) leaf: susceptibility and effect on urease activity. Phytother Res 18:358-361.

Boncristiano M, Paccani SR, Barone S, Ulivieri C, Patrussi L, Ilver D, Amedei A, D’Elios MM, Telford JL, Baldari CT. 2003. The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med 198:1887-1897.

Boren T, Falk P, Roth KA, Larson G, Normark S. 1993. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood-group antigens. Science 262:1892-1895.

Burne RA, Chen YM. 2000. Bacterial ureases in infectious diseases. Microbes Infect 2:533-542.

Cellini L, Campli ED, Masulli M, Bartolomeo SD, Allocati N. 1996. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). FEMS Immunol Med Microbiol 13:273-277.
Cellini L, Marzio L, Ferrero G, Del Vino A, Di Campli E, Grossi L, Toracchio S, Artese L. 2001. Transmission of Helicobacter pylori in an animal model. Dig Dis Sci 46:62-68.

Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. 1996. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and diseaseassociated virulence factors. Proc Natl Acad Sci USA 93:14648-14653.

Christie PJ and Vogel JP. 2000. Bacterial type IV secretion: conjugation systems adapted to deliver effector molecules to host cells. Trends Microbiol 8:354-360.

Clevenger S. 1958. The flavonols of Impatiens balsamina L.. Arch Biochem Biophyls 76:131-138.

Cover TL, Glupczynski Y, Lage AP, Burette A, Tummuru MKR, Perez-perez GI, Blaser MJ. 1995. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 33:1496-1500.

Ding ZS, Jiang FS, Chen NP, Lv GY, Zhu CG. 2008. Isolation and identification of an anti-tumor component from leaves of Impatiens balsamina. Molecules 13:220-229.

Eaton KA, Brooks CL, Morgan DR, Krakowka S. 1991. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 59:2470-2475.

Eaton KA, Suerbaum S, Josenhans C, Krakowka S. 1996. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect. Immun 64:2445-2448.

Evans DJ, Evans Jr.DG, Takemura T, Nakano H, Lampert HC, Graham DY, Granger DN, Kvietys PR. 1995. Characterization of the Helicobacter pylori neutrophil-activating protein. Infect Immun 63:2213-2220.

Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. 2007. Prevalence of primary clarithromycin resistance in Heliocbacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 59:783-785.

Fukumoto H, Yamaki M, Isoi K, Ishiguro K. 1996. Antianaphylactic effects of the principal compounds from the white petals of Impatiens balsamina L. Phytother Res 10:202-206.

Gadhi CA, Benharref A, Jana M, Lozniewski A. 2001. Anti-helicobacter pylori activity of Aristolochia paucinervis Pomel extracts. J Ethnopharmacol 75:203-205.

Galmiche A, Rassow J, Doye A, Cagnol S, Chambard JC, Contamin S, de Thillot V, Just I, Ricci V, Solcia E, Van Obberghen E, Boquet P. 2000. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J. 19:6361-6370.

Goodwin CS, Armstrong JA and Chilvers A. 1989. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. Nov. and Helicobacter mustelae comb. nov., respectively. Int J Syst Bacteriol 39:397-405.

Goodwin S. 1997. Detection of H. pylori infection by biopsy urease, histology, and culture. Ch. 2 in ”Helicobacter pylori protocols”, C. L. Clayton and H.A. T. Mobley (Ed.), pp7-18. Humana Press, Inc. NJ, USA.

Graham DY, Go MF, Evans DJ. 1992. Review article: gastric ammonium/ammonia, and Helicobacter pylori-the past, the present, and recommendations for future research. Aliment Pharmacol Ther 6:659-669.

Grubel P, Huang L, Masubuchi N, Stutzenberger FJ, Cave DR. 1998. Detection of Helicobacter pylori DNA in houseflices (Musca domestiea) on three coutinents. Lancet 352:788-789.

Gu Q, Xia HHX, Wang JD, Wong WM, Chan AOO, Lai KC, Chan CK, Yuen MF, Fung FMY, Wong KW, Lam SK, Wong BCY. 2006. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion 73:101-106.

Hazell SL, Lee A. 1986. Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcer. Lancet 2:15-17.

Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Boren T. 1998. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279:373-377.

Imazato S, Ebi N, Tarumi H, Russell RRB, Kaneko T, Ebisu S. 1999. Bactericidal activity and cytotoxicity of antibacterial monomer MDPB. Biomaterials 20:899-903.

Ishiguro K, Ohira Y, Oku H. 1998. Antipruritic Dinaphthofuran-7,12-dione Derivatives from the Pericarp of Impatiens balsamina. J Nat Prod 61:1126-1129

Ishiguro K, Oku H, Kato T. 2000 Testosterone 5a-Reductase Inhibitor Bisnaphthoquinone Derivative from Impatiens balsamina. Phytother Res 14:54-56
Karmarkar S, Koberda M, Momani J, Kotecki D, Garber R. 2004 Validated ion-exclusion chromatographic method for citrate and acetate in medical fluids. J Chromatogr A 1039:147-153.

Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FAK, Osato MS, Graham DY, Kwon DH. 2001. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 47:459-461.

Leo M, Tommasi N, Sanogo R, D’Angelo V, Germano MP, Bisignano G, Braca A. 2006. Triterpenoid saponins from Petleopsis suberosa stem bark. Phytochemistry 67: 2623-2629.

Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. 1988. Cytotoxin activity in broth culture filtrates of Campylobacter pylori. J Med Microbiol 26:93-99.

Leite KRM, Dnrini E, Canavez FC, Carvalho CM, Mitteldorf CATS, Lopes LHC. 2005. Helicobacter pylori and cagA gene detected by polymerase chain reaction in gastric biopsies: correlation with histological findings, proliferation and apoptosis. Sao Paulo Med J 123:113-118

Li Y, Xu C, Zhang Q, Liu JY, Tan RX. 2005. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol 98:329-333.

Lin H, Zhaofeng P, Lian SC, Ngoh KG, Swee NT. 2001. Separation of kaempferols in Impatiens balsamina flowers by capillary electrophoresis with electrochemical detection. J Chromatogr A 909:279-303

Lin JT, Wang JT, Wang TH, Wu MS, Lee TK, Chen CJ. 1993. Helicobacter pylori infection in a randomly selected population healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma: a seroprevalence study in Taiwan. Scand. J Gastroenterol 28:1067-1072.

Ling TKW, Leung WK, Lee CC, Ng EKW, Yung MY, Chung SSC, Sung JJY, Cheng AFB. 2002. The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter 7:327-329.

Little JE, Sproston TJ, Foote MW. 1948. Isolation and antifungal action of naturally occurring 2-methoxy-1,4-naphthoquinone. J Biol Chem 174: 335-342.

Lobstein L, Brenne X, Feist E, Metz N, Weniger B, Anton R. 2001. Quantitative determination of Naphthoquinones of Impatiens species. Phytochem. Phytochem Anal 12:202-205.

Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadstrom T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T. 2002. Helicobacter pylori SabA adhesion in persistent infection and chronic inflammation. Science 297:573-578.

Malekzadeh F, Ehsanifar H, Shahamat M, Levin M, Colwell RR. 2001. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. Int J Antimicrob Agents 18:85-88.

Marais Armelle, Bilardi C, Cantet F, Mendz GL, Megraud F. 2003. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 154:137-144.

Mark K, Irvin MM. 1998. Acentury of Helicobacter pylori. Digestion 59:1-15.

Marshall BJ, Goodwin CS. 1987. Revised nomenclature of Campylobacter pyloridis. Int J Syst Bacteriol 37:68-68.

Marshall BJ, Royce H, Annear DI, Goodwin CS, Pearman JW, Wrrren JR, Armstrong JA. 1984. Oringinal isolation of Campylobacter pyloridis from human gastric mucosa. Microbiol Lett 25:83-88.

Marshall BJ . 2002. Helicobacter pylori: 20 years on. Clin Med 2:147-52.

Megraud F. 2004. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1378-1384.

Megraud F, Neman-Simha V, Brugmann D. 1992. Further evidence of the toxic effect of ammonia produced by Helicobacter pylori urease on human epithelial cells. Infect Immun 60:1858-1863.

Monica PD, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. 2002. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in italy. Aliment Pharmacol Ther. 16:1269-1275.

Montecucco C and Rappuoli R. 2001. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat Rev Mol Cell Biol 2:457-466.

Nicola LJ, Souheil S, Philip MS. 1997. Capsaicin as an inhibitor of the growth of the gastric phathogen Helicobacter pylori. FEMS Microbiol Lett 146:223-227.

Nostro A, Cellini L, Bartolomeo SD, Campli ED, Cannatelli MA, Marzio L, Alonzo V. 2005. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother Res 19:198-202.

Nostro A, Cellini L, Bartolomeo SD, Cannatelli MA, Campli ED, Procopio F, Grande R, Marzio L, Alonzo V. 2006. Effects of combining extract (from propolis or Zingiber officinale) with clarithromycin on Helicobacter pylori. Phytother Res 20:187-190.

Ochi T, Shibata H, Higuti T, Kodama KH, Kusumi T, Takaishi Y. 2005. Anti-Helicobacter pylori compounds from Santalum album. J Nat Prod 68:819-824.

Ohsaki A, Takashima J, Chiba N, Kawamura M. 1999. Microanalysis of a selective potent anti-Helicobacter pylori compound in a Brazilian medicinal plant, Myroxylon peruiferum and the activity of analogues. Bioorg Med Chem Lett 9:1109-1112.

Oku H, Ishiguro K. 1999. Screening method for PAF antagonist substances: on the phenolic compounds from Impatiens balsamina L. Phytother Res 13: 521-525.

Oku H, Ishiguro K. 2001. Antipruritic and Antidermatitic Effect of Extract and Compounds of Impatiens balsamina L. in Atopic Dermatitis Model NC Mice. Phytother Res 15: 506-510.

Oku H, Ishiguro K. 2002. Cyclooxygenase-2 Inhibitory 1,4-Naphthoquinones f rom Impatiens balsamina L. Biol Pharm Bull 25:658-660.

O'' Toole PW. Lane MC, Porwollik S. 2000. Helicobacter pylori motility. Micro Infect 2:1207-1214.

Owen RJ. 2002. Molecular testing for antibiotic resistance in Helicobacter pylori. Gut 50:285-289.

Ozdemir A, Mas MR, Sahin S, Saglamkaya U, Ateskan U. 2001. Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. Quintessence Int 32:131-134.

Pakodi F, Abdel-Salam OM, Debreceni A, Mozsik G. 2000. Helicobacter pylori. One bacterium and a broad spectrum of human disease! An overview. J Physiol Paris 94:139-152.

Panichayupakaranant P. 2001. Naphthoqinone formation in cell cultures of Impatiens balsamina. Pharmaceutical Biology 39:293-296.

Park BS, Lee HK, Lee SE, Piao XL, Takeoka GR, Wong RY, Ahn YJ, Kim JH. 2006. Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori. J Ethnopharmacol 105:225-262.

Parsonnet J, Friedman GD, Orentreich N, Vogelman H. 1997. Risk for gastric cancer in people with CagA positive or Cag A negative Helicobacter pylori infection. Gut 40:297-301.

Perez-Perez GI, Rothenbacher D, Brenner H. 2004. Epidemiology of Helicobacter pylori infection. Helicobacter 9 Suppl 1:1-6.

Pharkphoom PY, Hiroshi N, Wanchai de-E, Ushio S. 1995. Naphthoquinones and coumarins from Impatiens Balsamina root cultures. Phytochemistry 40:1141-1143

Pinchuk IV, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Megraud F, Urdaci MC. 2001. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 45:3156-3161.

Pounder RE, Ng D. 1995. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9:33-39.

Price AB. 1999. Classification of gastritis-yesterday, today, and tomorrow. Verh Dtsch Ges Pathol 83:52-55.

Prinz C, Schwendy S, Voland P. 2006. H pylori and gastric cancer: Shifting the global burden. World J Gastroenterol 12:5458-5464.

Rad R, Gerhard M, Lang R, Schoniger M, Rosch T, Schepp W, Becker I, Wagner H, Prinz C. 2002. The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. J Immunol 168:3033-3041.

Rauws EAJ, Tytgat GNJ. 1995. 7 Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin Gastroenterol 9:529-547.

Reanmongkol W, Subhadhirasakul S, Panichayupakaranant P, Kim KM. 2003. Anti-allergic and antioxidative activities of some compounds from Thai medicinal plants. Pharm biol 8:592-597.

Rho TC, Bae EA, Kim DH, Oh WK, Kim BY, Ahn JS, Lee HS. 1999. Anti-helicobacter pylori activity of quinolone alkaloids from evodiae fructus. Biol Pharm Bull 22:1141-1143.

Rodriguez S, Wolfender JL, Hakizamungu E, Hostettmann K. 1995. An antifungal naphthoquinone, xanthones and secoiridoids from Swertia calycina. Planta Med 61:362-364.

Romero C, Medina E, Vargas J, Brenes M, Castro AD. 2007. In vitro activity of olive oil polyphenols against Helicobacter pylori. J Agric Food Chem 55:680-686.

Sanyal U, Bhattacharyya S, Patra A, Hazra B. 2003. Liquid chromatographic separation of derivatives of diospyrin, a bioactive bisnaphthoquinonoid plant-product, and analogous naphthyl compounds. J Chromatogr A 1017:225-232.

Satin B, Giudice GD, Bianca VD, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Mon-tecucco C, Rossi F. 2000. The neutrophil-activating protein(HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 191:1467-1476.

Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, Luckers AEG, Knol ECK, Festen HPM, Viergever PP, Lindeman J, Meuwissen SGM. 2000. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 46:615-621.

Schirm M, Soo EC, Aubry AJ, Austin J, Thibault P, Logan SM. 2003. Structural, genetic and functional characterization of the flagellin glycosylation process in Helicobacter pylori. Mol Microbiol 48:1579-1592.

Selbach M, Moese S, Hurwitz R, Hauck CR, Meyer TF, Backert S. 2003. The Helicobacter pylori CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. EMBO J 22:515-528.

Sharma SA, Tummuru MKR, Blaser MJ, Kerr LD. 1998. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-κB in gastric epithelial cells. J Immunol 160:2401-2407.

Sheu SM, Sheu BS, Yang HB, Li C, Chu TC, Wu JJ. 2002. Presence of iceA1 but not cagA, cagC, cagE, cagF, cagN, cagT, or orf13 genes of Helicobacter pylori is associated with more severe gastric inflammation in Taiwanese. J Formos Med Assoc 101:18-23.

Shin IS, Masuda H, Naohide K. 2004. Bactericidal activity of wasabi (Wasabia japonica) against Helicobacter pylori. Int J Food Microbiol 94:255-261.
Smith SR, Goldman MP, Worrel JA, Stoner SC. 1998. Eradication of Helicobacter pylori. Medical Update for Psychiatrists 4:99-104.

Stege PW, Davicino RC, Vega AE, Casali YA, Correa S, Micalizzi B. 2006. Antimicrobial activity of aqueous extracts of Larrea divaricata Cav (jarilla) against Helicobacter pylori. Phytomedicine 13:724-727.

Suerbaum S, Michetti P. 2002. Helicobacter pylori infection. N Engl J Med 347:1175-1186.

Tailor HR, Acland PD, Attenborough S, Cammue PAB, Evans JI, Osborn WR, Ray AJ, Rees BS, Broekaert FW. 1997. A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein. J Biol Chem 272:24480-24487.

Thongnopnua P, Boonleang J, Chunejitbhong V, Vanichseni W. 1991. Quantitative determination of 2-methoxy-1,4-naphthoquinone in plasma by high-performance liquid chromatography. Anal Sci 7:1529-1534.

Tong SJ, Chen J, Zhan Z, Yang DD, Liu YP. 2006. Expression of Helicobacter pylori cagA and vacA and their correlations with Helicobacter pylori infection in gastric cancer. WCJD 14:2632-2635.

Trieber CA, Taylor DE. 2002. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 184:2131-2140.

Wang YC, Huang TL. 2005. Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol Med Microbiol 43:295-300.

Wolfender JL, Rodriguez S, Hostettmann K, Hiller W. 1997. Liquid chromatography/ultra violet/mass spectrometric and liquid chromatography /nuclear magnetic resonance spectroscopic analysis of crude extracts of Gentianaceae species. Phytochem Anal 8:97-104.

Wu CC, Chou PY, Hu CT, Liu ZC, Lin CY, Tseng YH, Lin NT. 2005. Clinical relevance of the VacA, IceA, CagA, and FlaA genes of Helicobacter pylori strains isolated in eastern Taiwan. J Clin Microbiol 43:2913-2915.

Yamaguchi H, Osaki T, Kurihara N, Taguchi H, Hanawa T, Yamamoto T, Kamiya S. 1997. Heat-shock protein 60 homologue of Helicobacter pylori is associated with adhesion of H. pylori to human gastric epithelial cells. J Med Microbiol 46:825-831.

Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M, Azuma T. 2003. The cagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis 187:334-337.

Yang X, Summerhurst DK, Koval SF, Ficker C, Smith ML, Bernards MA. 2001. Isolation of an antimicrobial compound from Impatiens balsamina L. using bioassay-guided fractionation. Phytother Res 15:676-680.

Yee YK, Koo MWL. 2000. Anti-Helicobacter pylori activity of Chinese tea: in vitro study. Aliment Pharmacol Ther 14:635-638.

Yin S, Fan CQ, Dong L, Yue JM. 2006. Psoracorylifols A-E, five novel compounds with activity against Helicobacter pylori from seeds of Psoralea corylifolia. Tetrahedron 62:2569-2575.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top